![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RAB35 |
Gene summary for RAB35 |
![]() |
Gene information | Species | Human | Gene symbol | RAB35 | Gene ID | 11021 |
Gene name | RAB35, member RAS oncogene family | |
Gene Alias | H-ray | |
Cytomap | 12q24.23 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q15286 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11021 | RAB35 | LZE4T | Human | Esophagus | ESCC | 9.86e-04 | 4.25e-03 | 0.0811 |
11021 | RAB35 | LZE8T | Human | Esophagus | ESCC | 1.06e-07 | 1.78e-01 | 0.067 |
11021 | RAB35 | LZE22T | Human | Esophagus | ESCC | 7.48e-04 | 1.74e-01 | 0.068 |
11021 | RAB35 | LZE24T | Human | Esophagus | ESCC | 3.34e-13 | 2.85e-01 | 0.0596 |
11021 | RAB35 | P1T-E | Human | Esophagus | ESCC | 8.61e-04 | 2.27e-01 | 0.0875 |
11021 | RAB35 | P2T-E | Human | Esophagus | ESCC | 9.90e-27 | 4.76e-01 | 0.1177 |
11021 | RAB35 | P4T-E | Human | Esophagus | ESCC | 8.46e-15 | 2.87e-01 | 0.1323 |
11021 | RAB35 | P5T-E | Human | Esophagus | ESCC | 1.97e-14 | 1.08e-01 | 0.1327 |
11021 | RAB35 | P8T-E | Human | Esophagus | ESCC | 2.08e-12 | 2.53e-01 | 0.0889 |
11021 | RAB35 | P9T-E | Human | Esophagus | ESCC | 1.72e-08 | 3.29e-02 | 0.1131 |
11021 | RAB35 | P10T-E | Human | Esophagus | ESCC | 3.31e-09 | 5.81e-02 | 0.116 |
11021 | RAB35 | P11T-E | Human | Esophagus | ESCC | 4.87e-06 | 1.87e-01 | 0.1426 |
11021 | RAB35 | P12T-E | Human | Esophagus | ESCC | 1.01e-07 | 1.45e-01 | 0.1122 |
11021 | RAB35 | P15T-E | Human | Esophagus | ESCC | 2.14e-13 | 1.98e-01 | 0.1149 |
11021 | RAB35 | P16T-E | Human | Esophagus | ESCC | 3.00e-10 | 8.65e-02 | 0.1153 |
11021 | RAB35 | P17T-E | Human | Esophagus | ESCC | 4.59e-04 | 1.99e-01 | 0.1278 |
11021 | RAB35 | P19T-E | Human | Esophagus | ESCC | 3.71e-10 | 7.52e-01 | 0.1662 |
11021 | RAB35 | P20T-E | Human | Esophagus | ESCC | 1.32e-24 | 3.64e-01 | 0.1124 |
11021 | RAB35 | P21T-E | Human | Esophagus | ESCC | 3.24e-22 | 4.53e-01 | 0.1617 |
11021 | RAB35 | P22T-E | Human | Esophagus | ESCC | 4.57e-14 | 1.18e-01 | 0.1236 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
GO:000028115 | Esophagus | ESCC | mitotic cytokinesis | 58/8552 | 71/18723 | 4.34e-10 | 1.15e-08 | 58 |
GO:000091016 | Esophagus | ESCC | cytokinesis | 115/8552 | 173/18723 | 2.48e-08 | 4.68e-07 | 115 |
GO:006164015 | Esophagus | ESCC | cytoskeleton-dependent cytokinesis | 72/8552 | 100/18723 | 8.10e-08 | 1.39e-06 | 72 |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:00324565 | Esophagus | ESCC | endocytic recycling | 51/8552 | 73/18723 | 2.47e-05 | 2.10e-04 | 51 |
GO:199009017 | Esophagus | ESCC | cellular response to nerve growth factor stimulus | 38/8552 | 53/18723 | 1.10e-04 | 7.69e-04 | 38 |
GO:001988225 | Esophagus | ESCC | antigen processing and presentation | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
GO:199008916 | Esophagus | ESCC | response to nerve growth factor | 39/8552 | 56/18723 | 2.44e-04 | 1.51e-03 | 39 |
GO:00360106 | Esophagus | ESCC | protein localization to endosome | 18/8552 | 24/18723 | 3.43e-03 | 1.41e-02 | 18 |
GO:001619711 | Liver | Cirrhotic | endosomal transport | 93/4634 | 230/18723 | 1.01e-07 | 2.93e-06 | 93 |
GO:009887611 | Liver | Cirrhotic | vesicle-mediated transport to the plasma membrane | 59/4634 | 136/18723 | 1.46e-06 | 2.88e-05 | 59 |
GO:000726511 | Liver | Cirrhotic | Ras protein signal transduction | 119/4634 | 337/18723 | 8.16e-06 | 1.22e-04 | 119 |
GO:00198827 | Liver | Cirrhotic | antigen processing and presentation | 44/4634 | 106/18723 | 1.07e-04 | 1.10e-03 | 44 |
GO:00002812 | Liver | Cirrhotic | mitotic cytokinesis | 32/4634 | 71/18723 | 1.48e-04 | 1.42e-03 | 32 |
GO:00009105 | Liver | Cirrhotic | cytokinesis | 62/4634 | 173/18723 | 7.13e-04 | 5.33e-03 | 62 |
GO:199009011 | Liver | Cirrhotic | cellular response to nerve growth factor stimulus | 24/4634 | 53/18723 | 8.86e-04 | 6.37e-03 | 24 |
GO:199008911 | Liver | Cirrhotic | response to nerve growth factor | 25/4634 | 56/18723 | 9.03e-04 | 6.46e-03 | 25 |
GO:00616402 | Liver | Cirrhotic | cytoskeleton-dependent cytokinesis | 38/4634 | 100/18723 | 2.22e-03 | 1.35e-02 | 38 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAB35 | SNV | Missense_Mutation | c.416C>A | p.Ala139Asp | p.A139D | Q15286 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
RAB35 | SNV | Missense_Mutation | c.135N>G | p.Phe45Leu | p.F45L | Q15286 | protein_coding | deleterious(0) | benign(0.423) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
RAB35 | SNV | Missense_Mutation | novel | c.393N>T | p.Glu131Asp | p.E131D | Q15286 | protein_coding | tolerated(0.98) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RAB35 | SNV | Missense_Mutation | novel | c.587N>A | p.Arg196Gln | p.R196Q | Q15286 | protein_coding | tolerated(0.48) | benign(0.042) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAB35 | SNV | Missense_Mutation | c.206G>C | p.Arg69Pro | p.R69P | Q15286 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RAB35 | SNV | Missense_Mutation | c.280N>A | p.Glu94Lys | p.E94K | Q15286 | protein_coding | tolerated(0.13) | benign(0.163) | TCGA-CM-5349-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RAB35 | SNV | Missense_Mutation | c.416N>T | p.Ala139Val | p.A139V | Q15286 | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RAB35 | SNV | Missense_Mutation | novel | c.517N>G | p.Lys173Glu | p.K173E | Q15286 | protein_coding | tolerated(0.2) | benign(0.017) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RAB35 | SNV | Missense_Mutation | novel | c.469G>A | p.Val157Met | p.V157M | Q15286 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RAB35 | SNV | Missense_Mutation | c.65G>A | p.Ser22Asn | p.S22N | Q15286 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |